Methylene blue photodynamic therapy of antifungal-unresponsive (resistant) dermatophytosis

2025/06/30 by Ditte M L Saunte, Ditte Marie Lindhardt Saunte, Pernille Lindsø Andersen +3
Medicine · Veterinary · #Nail Diseases and Treatments #Infectious Diseases and Mycology #Antifungal resistance and susceptibility

paper · doi:10.1093/bjd/ljaf258

Abstract

This study was an exploratory, single-centre, open-label, uncontrolled investigation of methylene blue photodynamic therapy (MB-PDT) for the treatment of antifungal-resistant dermatophytosis. One-third of participants with antifungal-resistant dermatophytosis responded to two sessions of MB-PDT therapy. The small sample size and limited number of treatment sessions were possibly insufficient to investigate the true potential of this approach.

Related

• Photodynamic therapy: Innovative approaches for antibacterial and anticancer treatments
• Photosensitizers in antibacterial photodynamic therapy: an overview
• Susceptibility of bacterial species commonly found in abdominal abscesses to low‐dose photodynamic therapy: Effects of methylene blue concentration, fluence rate, and fluence
• Functionalization of cationic porphyrins with peripheral platinum(II) complexes to optimize photodynamic therapy against Candida- associated infections: a focus on denture stomatitis and burn wounds
• Miconazole Induces Fungistasis and Increases Killing of Candida albicans Subjected to Photodynamic Therapy†